ebolavirus
member
famili
filovirida
caus
sever
hemorrhag
fever
primat
respiratori
diseas
pig
induc
high
morbid
mortal
outbreak
western
africa
largest
ebola
viru
diseas
evd
outbreak
histori
result
death
receiv
unpreced
attent
worldwid
unfortun
evd
outbreak
occur
eastern
democrat
republ
congo
august
total
evd
case
report
includ
confirm
case
death
overal
case
fatal
rate
sinc
first
outbreak
report
five
differ
speci
ebolavirus
includ
ebola
viru
ebov
sudan
viru
sudv
reston
viru
restv
bundibugyo
viru
bdbv
forest
viru
tafv
identifi
genom
sequenc
differ
exclud
ebov
sudv
highest
mortal
outbreak
rate
among
speci
ebolavirus
sudv
emerg
least
six
time
averag
mortal
rate
multipl
vaccin
monoclon
antibodi
ebov
develop
effect
prevent
control
sudv
infect
therefor
urgent
need
develop
safe
efficaci
vaccin
sudv
ebov
genom
encod
nine
structur
protein
includ
surfac
envelop
glycoprotein
gp
membran
protein
matur
gp
protein
form
homotrim
surfac
infect
cell
virion
crucial
receptor
bind
viral
entri
host
immun
induct
make
gp
ideal
vaccin
target
number
candid
vaccin
ebov
demonstr
protect
lethal
ebov
challeng
anim
model
progress
clinic
trial
vaccin
includ
dna
vaccin
vaccin
base
viral
vector
recombin
adenoviru
vesicular
stomat
viru
vsv
proteinbas
vaccin
viruslik
particl
vlp
base
gp
notabl
number
candid
vaccin
current
clinic
phase
evalu
viral
vectorbas
vaccin
recombin
vesicular
stomat
viru
rvsv
base
recombin
adenoviru
vector
base
ebov
candid
vaccin
shown
highli
efficaci
ebov
infect
transmiss
numer
side
effect
fever
acut
arthriti
skin
lesion
report
addit
preexist
antibodi
cost
side
effect
also
consid
contrast
ebov
subunit
vaccin
may
offer
rel
safe
altern
induc
immun
respons
antigen
interest
howev
ebov
subunit
vaccin
would
face
hurdl
relat
immunogen
thu
requir
select
antigen
deliveri
vector
appropri
adjuv
even
adjuv
combin
display
heterolog
pathogenderiv
protein
surfac
bacteria
effect
safe
way
enhanc
immunogen
vaccin
gramposit
enhanc
matrixprotein
anchor
gempa
novel
surfac
display
system
wide
rang
biotechnolog
applic
especi
develop
vaccin
deliveri
system
gempa
surfac
display
system
consist
gem
particl
base
nonliv
nongenet
modifi
gramposit
lactococcu
lacti
l
lacti
bacteria
pa
deriv
l
lacti
peptidoglycan
hydrolas
acma
antigen
fuse
pa
anchor
effect
stabli
peptidoglycan
gem
particl
induc
antigenspecif
immun
respons
furthermor
vaccin
approach
base
gempa
surfac
display
system
elimin
risk
includ
recombin
dna
vaccin
safe
effect
inexpens
multifunct
platform
high
load
capac
protein
antigen
gempa
surfac
display
system
appli
middl
east
respiratori
syndromerel
coronaviru
vaccin
respiratori
syncyti
viru
vaccin
porcin
circoviru
type
vaccin
among
other
studi
develop
novel
bacteriumlik
particl
blp
vaccin
display
sudv
glycoprotein
use
gempa
surfac
display
system
novel
microconsensu
con
sudvgp
construct
design
weblogo
webbas
applic
pa
gene
sequenc
obtain
genbank
genbank
correspond
nucleotid
gene
codonoptim
highest
possibl
express
level
insect
cell
biochem
synthes
sangon
biotech
shanghai
china
egppa
fusion
gene
amplifi
pcr
use
synthet
oligonucleotid
primer
list
tabl
clone
xbai
kpnilinear
vector
clonexpress
ultra
one
step
clone
kit
vazym
biotech
transform
escherichia
coli
compet
cell
gener
recombin
bacmid
spodoptera
frugiperda
gibco
grand
island
ny
usa
insect
cell
transfect
recombin
bacmid
use
cellfectin
ii
reagent
follow
bactobac
express
system
manual
invitrog
waltham
usa
recombin
baculovirus
rbvegppa
harvest
day
post
transfect
defin
first
passag
premast
viru
virus
expand
cell
gener
viru
stock
indirect
immunofluoresc
assay
ifa
analysi
cell
grown
plate
infect
rbvegppa
h
fix
cold
aceton
min
room
temperatur
rt
subsequ
cell
incub
dilut
mous
monoclon
antibodi
prepar
store
laboratori
react
specif
sudv
gp
buffer
contain
bovin
serum
albumin
bsa
h
rt
three
wash
phosphat
buffer
salin
pb
contain
tween
pbst
dilut
fluorescein
isothiocyan
fitc
label
goat
antimous
igg
antibodi
sigma
st
loui
mo
usa
ad
evan
blue
h
rt
cell
observ
fluoresc
microscop
wash
western
blot
wb
express
fusion
protein
egppa
separ
sdspage
denatur
condit
protein
transfer
nitrocellulos
nc
membran
ge
healthcar
life
scienc
freiburg
germani
immunoblot
analysi
mous
monoclon
antibodi
detect
perform
horseradish
peroxid
hrp
conjug
goat
antimous
antibodi
enhanc
chemiluminesc
prepar
gem
particl
describ
detail
elsewher
briefli
l
lacti
cell
cultur
broth
oxoid
supplement
glucos
gem
particl
obtain
boil
harvest
l
lacti
trichloroacet
acid
tca
min
follow
extens
wash
pb
one
unit
u
defin
gem
particl
final
gem
particl
resuspend
pb
store
use
prepar
gembas
vaccin
conduct
follow
supernat
follow
superson
schizolysi
contain
egppa
fusion
protein
mix
gem
particl
min
rt
bind
egppagem
complex
collect
wash
five
time
steril
pb
resuspend
pb
produc
sblp
gem
particl
display
egp
antigen
surfac
target
determin
use
gpspecif
antibodi
wb
amount
bound
egppa
compar
bsa
standard
analysi
sdspage
result
use
softwar
quantiti
one
sdspage
wb
analys
gem
particl
egppagem
complex
treat
sd
load
buffer
min
separ
use
sdspage
gel
transfer
onto
nitrocellulos
nc
membran
wb
analysi
mous
monoclon
antibodi
ifa
analysi
gem
particl
bound
egppa
block
bsa
min
incub
primari
antibodi
mous
monoclon
antibodi
secondari
antibodi
fitclabel
goat
antimous
igg
perform
previous
describ
section
particl
view
imag
use
zeiss
microscop
incid
uv
illumin
zeiss
axiovis
digit
imag
system
zeiss
oberkochen
germani
total
two
batch
balbc
mice
six
eightweeksold
femal
purchas
changchun
institut
biolog
product
co
ltd
changchun
china
immun
poli
c
sigma
usa
aluminum
hydroxid
alum
thermo
usa
montanid
isa
isa
seppic
franc
purchas
research
complianc
welfar
ethic
laboratori
anim
china
gb
protocol
approv
anim
welfar
ethic
committe
veterinari
institut
academi
militari
medic
scienc
batch
mice
randomli
divid
group
immun
shown
tabl
batch
ii
mice
randomli
divid
group
vaccin
egppagem
alon
isa
plu
poli
c
compound
adjuv
two
batch
anim
experi
mice
control
group
receiv
volum
pb
time
point
immun
perform
studi
day
blood
sampl
collect
two
four
five
week
post
immun
immun
sera
collect
analyz
sudvspecif
antibodi
indirect
enzymelink
immunosorb
assay
elisa
briefli
assay
perform
polystyren
microtit
plate
corn
costar
usa
precoat
purifi
gp
protein
concentr
overnight
block
h
serial
dilut
serum
sampl
incub
h
secondari
antibodi
includ
hrpconjug
goat
antimous
igg
hrpconjug
hrpconjug
incub
h
develop
colorimetr
reaction
substrat
tetramethylbenzidin
sigma
usa
ad
well
reaction
stop
absorb
read
nm
titer
determin
highest
dilut
mean
absorb
sampl
greater
mean
absorb
dilut
control
serum
neutral
activ
sera
vaccin
mice
pseudovirus
contain
sudv
gp
base
human
immunodefici
viru
backbon
analyz
describ
previou
studi
briefli
dilut
serum
sampl
ad
cell
follow
addit
tissuecultur
infect
dose
pseudotyp
viru
prepar
volum
equal
serum
sampl
incub
h
addit
cell
h
incub
medium
replac
dmem
contain
fb
plate
incub
h
luciferas
activ
measur
use
infinit
neutral
activ
express
percentag
reduct
luciferas
activ
sampl
well
control
well
luciferas
activ
control
well
luciferas
activ
sampl
well
luciferas
activ
control
well
neutral
dose
calcul
use
graphpad
prism
splenocyt
isol
vaccin
mice
day
second
vaccin
cell
cultur
roswel
park
memori
institut
rpmi
medium
gibco
san
diego
ca
usa
contain
fb
stimul
without
purifi
sudv
gp
antigen
follow
incub
h
splenocyt
produc
interferongamma
interleukin
tumor
necrosi
factor
alpha
measur
use
mous
enzymelink
immunospot
elispot
kit
mous
elispot
kit
mabtech
ab
stockholm
sweden
accord
manufactur
instruct
spotform
cell
sfc
count
use
autom
elispot
reader
aid
elispot
readerispot
aid
gmbh
ger
detect
level
cytokin
interleukin
interleukin
splenocyt
isol
vaccin
mice
day
second
vaccin
cultur
cellsml
stimul
describ
h
supernat
stimul
cell
evalu
use
murin
elisa
kit
mabtech
ab
sweden
accord
manufactur
instruct
statist
analysi
perform
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
usa
signific
differ
two
mean
determin
unpair
student
ttest
data
present
mean
standard
error
unless
otherwis
indic
statist
signific
indic
p
p
p
p
shown
figur
accord
sequenc
prefer
characterist
design
new
synthet
microconsensu
gp
base
strain
sudv
avail
nation
center
biotechnolog
inform
ncbi
websit
strategi
design
egppa
fusion
protein
egp
fuse
pa
linker
shown
figur
ifa
result
show
compar
control
cell
cell
express
egppa
fusion
protein
emit
strong
green
fluoresc
figur
wb
show
egppa
success
express
present
kda
protein
supernat
precipit
superson
schizolysi
figur
e
furthermor
shown
figur
mous
monoclon
antibodi
react
specif
sblp
result
indic
recombin
egppa
protein
react
monoclon
antibodi
good
antigen
figur
product
process
sblp
shown
figur
cellfre
extract
contain
egppa
mix
gem
particl
wash
particl
subject
sdspage
analysi
figur
analysi
quantiti
one
indic
u
gem
particl
could
bind
approxim
egppa
fusion
protein
data
shown
surfac
locat
egppa
gem
particl
also
analyz
wb
figur
ifa
figur
monoclon
antibodi
wb
result
show
egppa
fusion
protein
bound
gem
particl
moreov
microscop
observ
indic
compar
gem
particl
alon
combin
gem
particl
egppa
fusion
protein
emit
strong
green
fluoresc
therefor
result
indic
egppa
fusion
protein
anchor
gem
particl
select
effect
adjuv
among
isa
plu
poli
c
poli
c
alum
isa
sblp
immun
week
immun
sera
sampl
obtain
analyz
figur
result
show
mice
immun
sblp
significantli
stronger
sudv
gpspecif
igg
neutral
antibodi
titer
mice
immun
pb
gem
particular
sblp
p
group
significantli
higher
antisudv
gp
igg
titer
sblp
alon
group
p
figur
furthermor
sera
sampl
vaccin
mice
test
neutral
activ
compar
adjuv
group
group
immun
isa
plu
poli
c
adjuv
greater
neutral
across
dilut
figur
c
therefor
isa
plu
poli
c
compound
adjuv
select
vaccin
experi
mice
compar
antibodi
respons
sudv
gp
induc
sblp
isa
plu
poli
c
induc
sblp
pseudotyp
viru
neutral
assay
data
show
sblp
p
group
exhibit
stronger
neutral
antibodi
sblp
group
figur
elisa
result
show
sera
mice
immun
sblp
isa
plu
poli
c
strongli
react
sudv
gp
protein
receiv
second
immun
reach
endpoint
titer
figur
contrast
antibodi
level
sera
sblp
immun
mice
show
signific
differ
sampl
harvest
week
week
second
immun
indic
antibodi
respons
plateau
figur
similar
phenomenon
also
found
sera
sudv
gpspecif
figur
figur
antibodi
week
post
immun
mice
immun
sblp
isa
plu
poli
c
sblp
interestingli
ratio
sblp
isa
plu
poli
c
signific
differ
sblp
figur
indic
sblp
induc
mix
thelper
thelper
immun
respons
confirm
sblp
isa
plu
poli
c
success
induc
enhanc
antibodi
respons
mice
next
evalu
tcell
respons
mice
follow
vaccin
secret
mous
splenocyt
measur
elispot
assay
shown
figur
sfc
indic
product
splenocyt
mice
immun
sblp
isa
plu
poli
c
significantli
mice
immun
sblp
indic
arm
adapt
immun
activ
investig
antigenspecif
cellular
immun
respons
cytokin
secret
splenocyt
assay
use
commerci
elisa
kit
level
cytokin
secret
splenocyt
mice
sblp
isa
plu
poli
c
sblp
alon
group
significantli
higher
secret
splenocyt
mice
pb
group
figur
secret
associ
profil
wherea
secret
associ
immun
respons
data
demonstr
sblp
vaccin
enhanc
secret
type
cytokin
type
cytokin
splenocyt
especi
presenc
adjuv
resurg
evd
epidem
eastern
drc
remind
us
still
threat
filoviru
infect
around
world
subunit
vaccin
promis
platform
prevent
ebov
infect
due
rel
safeti
induct
effect
immun
respons
avail
method
highlevel
product
gp
promis
candid
antigen
ebov
protein
vaccin
current
ebov
vaccin
target
viral
gp
antigen
notabl
previou
studi
shown
subunit
vaccin
base
egp
abl
protect
vaccin
mice
lethal
ebov
challeng
bazzil
j
et
al
prove
recombin
ebov
antigen
egp
incorpor
lipidbas
nanoparticl
could
effici
gener
germin
center
b
cell
polyfunct
cell
elicit
robust
neutral
antibodi
respons
furthermor
absenc
signal
sequenc
transmembran
domain
facilit
protein
express
consid
immun
effect
protein
express
chose
solubl
extracellular
domain
gp
protein
target
immunogen
studi
novel
exogen
antigen
deliveri
system
studi
base
nonliv
nongenet
modifi
l
lacti
cell
design
gem
particl
l
lacti
long
histori
use
food
recogn
safe
particl
bind
externallyad
heterolog
antigen
mean
pa
high
load
capac
high
affin
addit
chimer
anchor
fusion
protein
effici
strongli
select
bind
gem
particl
cultur
medium
rt
within
short
time
period
without
need
addit
purif
step
easier
obtain
purifi
antigen
blpbase
vaccin
viruslik
particl
vlp
vaccin
therefor
cost
product
vaccin
use
gempa
surfac
display
system
low
base
advantag
gempa
surfac
display
system
appli
develop
varieti
vaccin
present
studi
develop
novel
sblp
vaccin
use
gempa
surfac
display
system
found
sblp
immunogen
especi
promot
immun
respons
howev
studi
shown
immun
unadjuv
gp
nanoparticl
vaccin
intramuscular
im
inject
induc
antibodi
antibodi
gp
therefor
assum
outcom
might
relat
presenc
gem
particl
induc
immun
respons
use
vaccin
adjuv
skew
might
result
interact
tolllik
receptor
tlr
peptidoglycan
present
gem
particl
activ
shift
immun
respons
toward
respons
far
know
first
report
egpbas
sudv
subunit
vaccin
induc
mix
immun
respons
without
adjuv
import
mix
respons
mediat
protect
lethal
ebov
infect
demonstr
sever
report
improv
immun
effect
sblp
vaccin
use
isa
mix
poli
c
adjuv
isa
develop
commerci
product
made
waterinoilinwat
emuls
effect
improv
immun
respons
protect
poli
c
demonstr
potent
adjuv
abil
enhanc
host
innat
adapt
immun
respons
immun
mice
isa
mix
poli
c
adjuv
sblp
result
signific
increas
sudv
gpspecif
igg
sudv
pseudotyp
virusneutr
antibodi
titer
consid
import
correl
protect
use
ratio
indirect
method
evalu
induc
bias
respect
immun
respons
interestingli
ratio
show
signific
differ
sblp
alon
adjuv
howev
studi
isa
poli
c
adjuv
induc
immun
respons
assum
presenc
gem
particl
may
chang
bia
investig
warrant
confirm
immunolog
adjuv
function
gem
particl
sblp
subunit
vaccin
ebov
vaccin
simultan
stimul
specif
humor
cellular
immun
essenti
effect
vaccin
protect
cellular
immun
respons
associ
product
sever
cytokin
includ
result
show
sblp
result
signific
increas
secret
cytokin
level
also
significantli
increas
presenc
isa
plu
poli
c
adjuv
result
prove
sblp
boost
immun
respons
pathway
consid
import
correl
protect
conclus
success
construct
sblp
vaccin
display
egp
protein
antigen
studi
result
clearli
demonstr
sblp
isa
plu
poli
c
high
immunogen
could
elicit
robust
specif
humor
cellular
immun
vaccin
mice
protect
efficaci
evalu
sblp
vaccin
anim
model
must
perform
futur
studi
result
strongli
support
potenti
gempa
particl
display
deliveri
system
subunit
vaccin
develop
addit
effort
underway
optim
sblp
primari
immun
respons
effect
